Zoetis Inc. — Ethics Grade B-

Zoetis Inc. receives an overall ethics grade of B- (64/100) on CancelCo's corporate accountability database. Sector: Pharmaceuticals. Market cap: Large Cap.

Category scores

• labor: 70
• privacy: 85
• consumer: 62
• environment: 58
• humanRights: 75

Documented incidents (3)

• Veterinary Opioid Marketing (medium, 2022) — Concerns were raised regarding the aggressive marketing of opioid-based pain relief for pets, mirroring some of the tactics used in human pharmaceutical marketing. Critics argue this contributes to the broader availability of controlled substances.
• Pharmaceutical Waste Disposal (medium, 2019) — Research indicated that manufacturing residues from animal health products were detected in local waterways near production facilities. These residues can contribute to antimicrobial resistance in the environment.
• Diagnostic Equipment Exclusivity (medium, 2020) — The company faced scrutiny for lock-in contracts that prevented veterinarians from using third-party diagnostic consumables, allegedly inflating costs for pet owners.

Documented good deeds

• A.L.P.H.A. Initiative — The African Livestock Productivity and Health Advancement initiative has reached over 100,000 farmers, providing medicine and veterinary training to improve food security.

Ethical alternatives

• IDEXX Laboratories — Better ESG rating in waste management and clinical ethics.